




Mouse IgA Isotype Control

Cat. No.	Format	Size
0106-01	Purified (UNLB)	1.0 mg
0106-02	Fluorescein (FITC)	100 tests
0106-08	Biotin (BIOT)	0.5 mg
0106-09	R-phycoerythrin (PE)	100 tests
0106-11	Allophycocyanin (APC)	100 tests
0106-13	Spectral Red [®] (SPRD)	100 tests
0106-14	Low Endotoxin, Azide-Free (LE/AF)	0.5 mg
0106-16	R-phycoerythrin-Cyanine 5.5 (PE/CY5.5)	100 tests
0106-17	R-phycoerythrin-Cyanine 7 (PE/CY7)	100 tests
0106-18	Allophycocyanin-Cyanine 5.5 (APC/CY5.5)	100 tests
0106-19	Allophycocyanin-Cyanine 7 (APC/CY7)	100 tests



ELISA plate was coated with serially diluted Mouse IgA-UNLB (SB Cat. No. 0106-01). Immunoglobulin was detected with Goat Anti-Mouse IgG, Human ads-BIOT (SB Cat. No. 1030-08), Goat Anti-Mouse IgA-BIOT (SB Cat. No. 1040-08), and Goat Anti-Mouse IgM, Human ads-BIOT (SB Cat. No. 1020-08) followed by Streptavidin-HRP (SB Cat. No. 7100-05) and quantified.

Overview

Clone	S107
Isotype	Mouse IgA _κ
Specificity	C-carbohydrate

Applications

FC – Quality tested ¹⁸
 ELISA – Quality tested ¹⁻¹⁷
 FLISA – Quality tested
In vivo control – Reported in literature ^{19,20}

Working Dilutions

Flow Cytometry	Purified (UNLB) antibody	≤ 1 µg/10 ⁶ cells
	BIOT conjugate	≤ 1 µg/10 ⁶ cells
	FITC, PE, APC, SPRD, PE/CY5.5, PE/CY7, APC/CY5.5, and APC/CY7 conjugates	10 µL/10 ⁶ cells
	For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL	
ELISA	Purified (UNLB) antibody	1 - 5 µg/mL
Other Applications	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.	

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) antibody is supplied as 1.0 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate supplied as 100 tests in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) and allophycocyanin (APC) conjugates are supplied as 100 tests in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Spectral Red[®] (SPRD), R-phycoerythrin-Cyanine 5.5 (PE/CY5.5), R-phycoerythrin-Cyanine 7 (PE/CY7), allophycocyanin-Cyanine 5.5 (APC/CY5.5), and allophycocyanin-Cyanine 7 (APC/CY7) conjugates are supplied as 100 tests in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. **Aliquot and store at or below -20°C.**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Dunn LA, Upcroft JA, Fowler EV, Matthews BS, Upcroft P. Orally administered *Giardia duodenalis* extracts enhance an antigen-specific antibody response. *Infect Immun.* 2001;69:6503-10. (ELISA)
2. Hocheppied T, Wullaert A, Berger FG, Baumann H, Brouckaert P, Steidler L, et al. Overexpression of α_1 -acid glycoprotein in transgenic mice leads to sensitisation to acute colitis. *Gut.* 2002;51:398-404. (ELISA)
3. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. *J Immunol.* 2003;170:3528-33. (ELISA)
4. Wang J, Anders RA, Wu Q, Peng D, Cho JH, Sun Y, et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. *J Clin Invest.* 2004;113:826-35. (ELISA)
5. Chen C, Louie S, Shi HN, Walker WA. Preinoculation with the probiotic *Lactobacillus acidophilus* early in life effectively inhibits murine *Citrobacter rodentium* colitis. *Pediatr Res.* 2005;58:1185-91. (ELISA)
6. Genestier L, Taillardat M, Mondiere P, Gheit H, Bella C, Defrance T. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. *J Immunol.* 2007;178:7779-86. (ELISA)
7. Arnaboldi PM, Roth-Walter F, Mayer L. Suppression of Th1 and Th17, but not Th2, responses in a CD8⁺ T cell-mediated model of oral tolerance. *Mucosal Immunol.* 2009;2:427-38. (ELISA)
8. Patterson HC, Kraus M, Wang D, Shahsafaei A, Henderson JM, Seagal J, et al. Cytoplasmic Ig α serine/threonines fine-tune Ig α tyrosine phosphorylation and limit bone marrow plasma cell formation. *J Immunol.* 2011;187:2853-8. (ELISA)
9. Generoso SV, Viana ML, Santos RG, Arantes RM, Martins FS, Nicoli JR, et al. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed *Saccharomyces boulardii*. *Eur J Nutr.* 2011;50:261-9. (ELISA)
10. Batista MA, Nicoli JR, Martins Fdos S, Machado JA, Arantes RM, Quirino IE, et al. Pretreatment with citrulline improves gut barrier after intestinal obstruction in mice. *JPN J Parenter Enteral Nutr.* 2012;36:69-76. (ELISA)
11. Chapman JR, Barral P, Vannier J, Borel V, Steger M, Tomas-Loba A, et al. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. *Mol Cell.* 2013;49:858-71. (ELISA)
12. Steinberg RS, Silva LC, Souza TC, Lima MT, de Oliveira NL, Vieira LQ, et al. Safety and protective effectiveness of two strains of *Lactobacillus* with probiotic features in an experimental model of salmonellosis. *Int J Environ Res Public Health.* 2014;11:8755-76. (ELISA)
13. Mann JF, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, et al. Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes. *J Virol.* 2014;88:6959-69. (ELISA)
14. Alsadeq A, Hobeika E, Medgyesi D, Kläsener K, Reth M. The role of the Syk/Shp-1 kinase-phosphatase equilibrium in B cell development and signaling. *J Immunol.* 2014;193:268-76. (ELISA)
15. Goverse G, Olivier BJ, Molenaar R, Knippenberg M, Greuter M, Konijn T, et al. Vitamin A metabolism and mucosal immune function are distinct between BALB/c and C57BL/6 mice. *Eur J Immunol.* 2015;45:89-100. (ELISA)
16. Vogelzang A, McGuire HM, Liu SM, Gloss B, Mercado K, Earls P, et al. IL-21 contributes to fatal inflammatory disease in the absence of Foxp3⁺ T regulatory cells. *J Immunol.* 2014;192:1404-14 (ELISA)
17. Santos RG, Quirino IE, Viana ML, Generoso SV, Nicoli JR, Martins FS, et al. Effects of nitric oxide synthase inhibition on glutamine action in a bacterial translocation model. *Br J Nutr.* 2014;111:93-100. (ELISA)
18. Benhamron S, Tirosh B. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation and loss of marginal zone B cells. *Eur J Immunol.* 2011;41:2390-6. (FC)
19. Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S, et al. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. *Cell Death Differ.* 2005;12:649-58. (*In vivo* control)
20. Seibert CW, Rahmat S, Krause JC, Eggink D, Albrecht RA, Goff PH, et al. Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs. *J Virol.* 2013;87:7793-804. (*In vivo* control)

Spectral Red[®] is a registered trademark of Southern Biotechnology Associates, Inc.

Spectral Red[®] is a PE/CY5 tandem conjugate.

Cy[®] is a registered trademark of GE Healthcare.